124 related articles for article (PubMed ID: 15240746)
1. Changes to peptide structure, not concentration, contribute to expansion of the lowest avidity cytotoxic T lymphocytes.
Leggatt GR; Narayan S; Fernando GJ; Frazer IH
J Leukoc Biol; 2004 Oct; 76(4):787-95. PubMed ID: 15240746
[TBL] [Abstract][Full Text] [Related]
2. Secondary immunisation with high-dose heterologous peptide leads to CD8 T cell populations with reduced functional avidity.
Narayan S; Choyce A; Fernando GJ; Leggatt GR
Eur J Immunol; 2007 Feb; 37(2):406-15. PubMed ID: 17274003
[TBL] [Abstract][Full Text] [Related]
3. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
Janicki CN; Jenkinson SR; Williams NA; Morgan DJ
Cancer Res; 2008 Apr; 68(8):2993-3000. PubMed ID: 18413769
[TBL] [Abstract][Full Text] [Related]
4. Immunisation route-dependent expression of IL-4/IL-13 can modulate HIV-specific CD8(+) CTL avidity.
Ranasinghe C; Ramshaw IA
Eur J Immunol; 2009 Jul; 39(7):1819-30. PubMed ID: 19582753
[TBL] [Abstract][Full Text] [Related]
5. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.
Zeh HJ; Perry-Lalley D; Dudley ME; Rosenberg SA; Yang JC
J Immunol; 1999 Jan; 162(2):989-94. PubMed ID: 9916724
[TBL] [Abstract][Full Text] [Related]
6. Relevance of peptide avidity to the T cell receptor for cytomegalovirus-specific ex vivo CD8 T cell cytotoxicity.
Villacres MC; Lacey SF; Auge C; Longmate J; Leedom JM; Diamond DJ
J Infect Dis; 2003 Sep; 188(6):908-18. PubMed ID: 12964124
[TBL] [Abstract][Full Text] [Related]
7. In vitro expansion distorts the detectable pattern of specific recognition of in vivo primed cytotoxic T lymphocyte populations.
Schirmbeck R; Deppert W; Kury E; Reimann J
Cell Immunol; 1993 Jul; 149(2):444-9. PubMed ID: 8330320
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
[TBL] [Abstract][Full Text] [Related]
9. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
10. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
11. The hypervariable immunodominant NP418-426 epitope from the influenza A virus nucleoprotein is recognized by cytotoxic T lymphocytes with high functional avidity.
Boon AC; de Mutsert G; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
J Virol; 2006 Jun; 80(12):6024-32. PubMed ID: 16731941
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells.
Waeckerle-Men Y; Starke A; Wüthrich RP
Nephrol Dial Transplant; 2007 Jun; 22(6):1527-36. PubMed ID: 17339272
[TBL] [Abstract][Full Text] [Related]
13. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-12 increases proliferation and interferon-gamma production but not cytolytic activity of human antigen-specific effector memory cytotoxic T lymphocytes: power of the effect depends on the functional avidity of the T cell and the antigen concentration.
Bontkes HJ; Ruizendaal JJ; Kramer D; Meijer CJ; Schreurs MW; Hooijberg E
Hum Immunol; 2005 Nov; 66(11):1137-45. PubMed ID: 16571414
[TBL] [Abstract][Full Text] [Related]
15. Suppression of choroidal neovascularization by dendritic cell vaccination targeting VEGFR2.
Mochimaru H; Nagai N; Hasegawa G; Kudo-Saito C; Yaguchi T; Usui Y; Kurihara T; Koto T; Satofuka S; Shinoda H; Ozawa Y; Tsubota K; Kawakami Y; Ishida S
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4795-801. PubMed ID: 17898306
[TBL] [Abstract][Full Text] [Related]
16. Memory Th1 cells augment tumor-specific CTL following transcutaneous peptide immunization.
Hosoi A; Takeda Y; Furuichi Y; Kurachi M; Kimura K; Maekawa R; Takatsu K; Kakimi K
Cancer Res; 2008 May; 68(10):3941-9. PubMed ID: 18483280
[TBL] [Abstract][Full Text] [Related]
17. Differential expansion and survival of high and low avidity cytotoxic T cell populations during the immune response to a viral infection.
Alexander-Miller MA
Cell Immunol; 2000 Apr; 201(1):58-62. PubMed ID: 10805974
[TBL] [Abstract][Full Text] [Related]
18. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K
Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040
[TBL] [Abstract][Full Text] [Related]
19. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
20. CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes.
Love VA; Grabie N; Duramad P; Stavrakis G; Sharpe A; Lichtman A
Circ Res; 2007 Aug; 101(3):248-57. PubMed ID: 17569889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
